Despite the fact that Sales of Acomplia Lag, Sanofi Still Has High Hopes
With sales of Acomplia (rimonabant) lagging in
the several dozen countries where it is on the market, Sanofi-Aventis
executives had little to say about their pioneering obesity treatment
in a report to analysts on Feb. . But that hardly means they have …